Preferences of choice between original and generic medicines: pharmaceutical support for patients with coronary heart disease and comorbid conditions
DOI:
https://doi.org/10.14739/mmt.2025.1.317003Keywords:
coronary heart disease, pharmaceutical care, adherence to treatment, availability of medicines, clinical effectiveness, assortment policyAbstract
Ukraine ranks fourth globally in mortality from coronary heart disease (CHD). The negative socio-economic impact of martial law is likely to exacerbate this situation. Therefore, the use of original and generic drugs in pharmacotherapy deserves special attention as it may affect the availability of medicines and adherence to treatment.
Aim. To study the influence of preferences of doctors, pharmacists, and patients regarding the use of original and generic medicines in the pharmacotherapy of CHD with comorbid conditions, to further identify factors affecting drug availability and patient adherence to treatment.
Materials and methods. We analysed the results of an anonymous online survey conducted with the help of Google Forms at the Department of Cardiology of the Shupyk National Healthcare University of Ukraine, from June to September 2024. Statistical, analytical, bibliographic methods, as well as synthesis, analysis, deduction, and induction techniques were used.
Results. The reliability of the influence of clinical efficacy and safety of drugs (χ2 = 5.653, p = 0.017) on their choice in the pharmacotherapy of CHD with comorbidities for doctors 87.4 % [CI 95 % 87.400 ± 0.004, p < 0.0001], pharmacists 79.1 % [CI 95 % 79.10 ± 0.02, p < 0.0001] and patients 91.1 % [CI 95 % 91.100 ± 0.007, p < 0.0001] is determined in the study. The absence of certain drugs in the “Affordable Medicines” Reimbursement Program in Ukraine decreases interest among healthcare professionals in the program (χ2, adjusted for plausibility = 4.011, p = 0.050) and negatively affects access to clinically effective and safe drugs for patients with CHD with comorbidities (χ2 = 3.350, p = 0.067).
Conclusions. The preferences of choice of doctors, pharmacists, and patients between original and generic medicines are influenced by the clinical effectiveness and safety of the drugs. The absence of certain medicines that are recommended by clinical protocols and guidelines for managing CHD with comorbid conditions in the Reimbursement Program, reduces healthcare professionals’ engagement with the program and negatively affects the availability of effective pharmacotherapy and treatment adherence.
References
The global use of medicines 2024: Outlook to 2028 [Internet]. Iqvia.com. [cited 2025 Jan 3]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028
Noncommunicable diseases [Internet]. Who.int. 2023 Dec 23 [cited 2025 Jan 3]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
Health profile Ukraine [Internet]. World Life Expectancy. [cited 2025 Jan 3]. Available from: https://www.worldlifeexpectancy.com/country-health-profile/ukraine
Ferrannini G, Tuomilehto J, De Backer G, Kotseva K, Mellbin L, et al. Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies. Lancet Diabetes Endocrinol. 2024;12(11):790-8. doi: https://doi.org/10.1016/S2213-8587(24)00201-8
Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021;28(4):370-9. doi: https://doi.org/10.1177/2047487320908698
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi: https://doi.org/10.1161/CIR.0000000000001168
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-537. doi: https://doi.org/10.1093/eurheartj/ehae177
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. doi: https://doi.org/10.1093/eurheartj/ehad192
Cardiovascular diseases: A handbook for pharmacists. The Hague: International Pharmaceutical Federation; 2022. Available from: https://www.fip.org/file/5251
Ahmed A, Guo P, Jalal Z. A systematic review investigating the role and impact of pharmacist interventions in cardiac rehabilitation. Int J Clin Pharm. 2023;45(2):320-9. doi: https://doi.org/10.1007/s11096-022-01517-1
Gao L, Han Y, Jia Z, Wang P, Zhang M, Ma T, et al. Impact of continuous pharmaceutical care led by clinical pharmacists during transitions of care on medication adherence and clinical outcomes for patients with coronary heart disease: a prospective cohort study. Front Pharmacol. 2023;14:1249636. doi: https://doi.org/10.3389/fphar.2023.1249636
Motlohi NF, Wiafe E, Mensah KB, Padayachee N, Petrus R, Bangalee V. A systematic review of the role of community pharmacists in the prevention and control of cardiovascular diseases: the perceptions of patients. Syst Rev. 2023;12(1):160. doi: https://doi.org/10.1186/s13643-023-02338-7
Östbring MJ. Pharmaceutical care in coronary heart disease [dissertation on the Internet]. Kalmar: Linnaeus University; 2021 [cited 2025 Jan 2]. Available from: http://www.diva-portal.org/smash/get/diva2:1537931/FULLTEXT01.pdf
Verkhovna Rada of Ukraine. Pro likarski zasoby. [On Medicinal Products]. Law of Ukraine dated 2022 Jul 28 No. 2469-IX. [Internet]. 2022 [cited 2024 Jun 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/2469-20#Text
Lanza VE, Silva GO, Quiroga CC, Cavalcante MA, Barroso WK, Brandão AA, et al. Therapeutic adherence according to the Morisky scale in patients with hypertension. International Journal of Cardiovascular Sciences. 2024;37. doi: https://dx.doi.org/10.36660/ijcs.20220138
Ministry of Health of Ukraine. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy "Stabilna ishemichna khvoroba sertsia" [Unified clinical protocol for primary, secondary (specialized) and tertiary (highly specialized) medical care "Stable ischemic heart disease"]. Order dated 2021 [Internet]. 2021 Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2021/12/2021_2857_ykpmd_stabihs.pdf
Ministry of Health of Ukraine. Nastanova Derzhavna otsinka medychnykh tekhnolohii dlia likarskykh zasobiv [State medical technology assessment for medicinal products. Guidelines ST-N MOZU 42-9.1:2021]. 2021. Available from: https://moz.gov.ua/uploads/5/29631-dn_593_29_03_2021_dod.pdf
Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations | Orange Book. Fda.gov. [cited 2025 Jan 3]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
Bilousova N, Soloviov S, Kabachna A. [Theoretical and methodological principles of evaluation of Health Technology Assessment]. Kyiv, Ukraine: TOV "Iurka Liubchenka"; 2023. Ukrainian. Available from: https://lib.iitta.gov.ua/id/eprint/736032/
Ministry of Health of Ukraine. Plan vidnovlennia systemy okhorony zdorovia Ukrainy vid naslidkiv viiny na 2022‐2032 roky [Plan for the restoration of the healthcare system of Ukraine from the consequences of the war for 2022-2032]. 2022 Jul 21 [cited 2025 Jan 1]. Ukrainian. Available from: https://moz.gov.ua/uploads/ckeditor/Новини/21-07-2022-Draft-Ukraine%20HC%20System%20Recovery%20Plan-2022-2032_UKR.pdf
Leclerc J, Thibault M, Midiani Gonella J, Beaudoin C, Sampalis J. Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis. Drugs. 2020;80(7):697-710. doi: https://doi.org/10.1007/s40265-020-01296-x
Zhao B, Wu J, Lu C, Feng XL. Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study. Clin Transl Sci. 2024;17(4):e13779. doi: https://doi.org/10.1111/cts.13779
Tian Y, Reichardt B, Dunkler D, Hronsky M, Winkelmayer WC, Bucsics A, et al. Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study. Sci Rep. 2020;10(1):5964. doi: https://doi.org/10.1038/s41598-020-62318-y
Premanath M, Kulkarni P. Generic drugs or branded generics, which one you prefer to prescribe? APIK Journal of Internal Medicine. 2024;12(3):195-6. doi: https://doi.org/10.4103/ajim.ajim_119_23
Kirsanov D. Aptechnyi prodazh za pidsumkamy I pivrichchia 2024 r [Pharmacy sales in the first half of 2024]. Apteka online. 2024;(28/29). Ukrainian. Available from: https://www.apteka.ua/article/698730
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi: https://doi.org/10.1093/eurheartj/ehae178
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJ, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-414. doi: https://doi.org/10.1093/eurheartj/ehae176
Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Brouse S, Butler J, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444-88. doi: https://doi.org/10.1016/j.jacc.2023.12.024
Ministry of Health of Ukraine. Pro zatverdzhennia Poriadku vkliuchennia (vykliuchennia) likarskykh zasobiv do (z) Natsionalnoho pereliku osnovnykh likarskykh zasobiv ta/abo do (z) nomenklatur likarskykh zasobiv, shcho zakupovuiutsia za koshty derzhavnoho biudzhetu dlia vykonannia prohram ta zdiisnennia tsentralizovanykh zakhodiv z okhorony zdorovia, iz zastosuvanniam derzhavnoi otsinky medychnykh tekhnolohii. Order dated 2022 Jan 4, No. 4 [Internet]. 2024 Jul 5 [cited 2025 Jan 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/z0095-22#Text
Ministry of Health of Ukraine. Pro zatverdzhennia perelikiv hranychnykh optovo-vidpusknykh tsin na likarski zasoby i medychni vyroby, yaki pidliahaiut reimbursatsii za prohramoiu derzhavnykh harantii medychnoho obsluhovuvannia naselennia, stanom na 01 lypnia 2024 roku. Order dated 2024 Jul 5 [cited 2025 Jan 1]. Ukrainian. Available from: https://moz.gov.ua/storage/uploads/ab1f1bd6-93ef-44f2-8221-44b2ff54d72a/dn_1172_05072024_dod.pdf
Bilousova N. [Personalized approaches to the provision of pharmaceutical care: a modern demand of Ukrainian society]. In: Management and marketing in the modern economy, science, education and practice, in Digital library NAES of Ukraine. Proceedings of the 10th international scientific and practical distance conference. Kharkiv, Ukraine: NUPh; 2024. p. 151-9. Ukrainian. Available from: https://lib.iitta.gov.ua/id/eprint/740315/
Reilly K. The pharmacist’s guide to acute coronary syndrome [Internet]. US Pharm. 2020;45(2):HS7-HS12. [cited 2025 Jan 5]. Available from: https://www.uspharmacist.com/article/the-pharmacists-guide-to-acute-coronary-syndrome
van Loon WE, Lambert M, Heringa M, Bouvy ML, Taxis K. Community pharmacists' attitudes towards checking prescriptions: a cross-sectional survey. Int J Pharm Pract. 2024;32(5):363-8. doi: https://doi.org/10.1093/ijpp/riae030
Nalezhna aptechna praktyka: Standarty yakosti aptechnykh posluh (Spilna nastanova MFF/VOOZ z NAP) [Good pharmacy practice: Standards of quality of pharmacy services (Joint guideline of the IFF/WHO with the National Health Service)]. 2011 Jan 1 [cited 2025 Jan 1]. Ukrainian. Available from: https://zakon.rada.gov.ua/laws/show/897_009#Text
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Dolzhenko M. M., Bilousova N. A., Nesukai V. A., Simahina T. V., Kozhuharova N. A.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
